NMT Medical Receives FDA Approval to Modify MIST II PFO Migraine Study in the United States (RedNova)
BOSTON, Aug. 31 /PRNewswire-FirstCall/ -- NMT Medical, Inc. announced today that it has received conditional approval from the U.S.

NMT Medical Receives FDA Approval to Modify MIST II PFO Migraine Study in the United States (PR Newswire via Yahoo! Finance)
NMT Medical, Inc. announced today that it has received conditional approval from the U.S. Food and Drug Administration for modifications the Company requested to its current investigational device exemption for its pivotal PFO /migraine clinical study, MIST II.

Director of FDA's Center for Drug Evaluation and Research (CDER), Dr. Steven Galson, to Participate at 'Health Care (Market Wire via Yahoo! Finance)
Dow Jones VentureWire announced today that its second annual 'Health Care Innovations: Finding and Funding the Cures of Tomorrow' conference, to be held on Tuesday and Wednesday, Sept. 12-13, 2006, at the Sofitel San Francisco Bay hotel in Redwood City, Calif. (http://healthcare.dowjones.com), will include a 'Keynote Interview' -- 'What is the FDA thinking?' -- with Steven Galson, M.D., Director